+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt



Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt



Clinical Infectious Diseases 23(2): 337-340



During an outbreak of type E foodborne botulism in Cairo in 1991, an investigational equine F(ab')2 "despeciated" heptavalent botulism immune globulin (dBIG) was provided to the Egyptian Ministry of Health by the U.S. Army. Of 54 patients known to have been treated with antitoxins, 4 received commercially available trivalent antitoxins, 45 received dBIG, and 5 received both commercial antitoxin and dBIG. Physicians recorded side effects in 10 (22%) of 45 patients who received dBIG; in nine cases, reactions were considered "mild," and in one case they were believed to be serum sickness. In contrast, possible serum sickness during hospitalization was recorded for two of four patients who were receiving commercial antitoxins. No complications of therapy were noted for any patient who was receiving both antitoxin types. In a separate study, 31 patients were contacted about their reactions to the antitoxin by telephone after discharge from the hospital. Seven (54%) of 13 patients attributed symptoms that they experienced while they were hospitalized to receipt of dBIG, while four (44%) of nine patients who indicated that they had received commercial antitoxins and one (20%) of five who received both commercial antitoxin and dBIG reported side effects before discharge. Data on the efficacy of the antitoxins were not obtained. In our experience, equine dBIG was at least as safe as commercially available antitoxins in treating type E foodborne botulism.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046037196

Download citation: RISBibTeXText

PMID: 8842274

DOI: 10.1093/clinids/23.2.337


Related references

Experience with the Use of an Investigational F( ab)2Heptavalent Botulism Immune Globulin of Equine Origin during an Outbreak of Type E Botulism in Egypt. Clinical Infectious Diseases 23(2): 337-340, 1996

Infant botulism: a 30-year experience spanning the introduction of botulism immune globulin intravenous in the intensive care unit at Childrens Hospital Los Angeles. Pediatrics 120(6): E1380, 2007

Initial recovery and rebound of type f intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin. Clinical Infectious Diseases 53(9): E125-E128, 2011

Safety of the investigational new drug heptavalent botulism antitoxin. American Journal of Tropical Medicine & Hygiene 47(4 Suppl. ): 204, 1992

Botulism immune globulin for infant botulism arrives--one year and a Gulf War later. Western Journal of Medicine 156(2): 197-198, 1992

Infant botulism and botulism immune globulin in the UK: a case series of four infants. Archives of Disease in Childhood 97(5): 459-460, 2012

Efficacy of Human Botulism Immune Globulin for the Treatment of Infant Botulism: The First 12 Years Post Licensure. Journal of Pediatrics 193: 172-177, 2018

Infant Botulism and Indications for Administration of Botulism Immune Globulin. Pediatric Emergency Care 30(2): 125-127, 2014

Clinical trial of botulism immune globulin for infant botulism. Western Journal of Medicine 154(1): 103, 1991

Human botulism immune globulin for the treatment of infant botulism. New England Journal of Medicine 354(5): 462-471, 2006

Infant botulism and indications for administration of botulism immune globulin. Pediatric Emergency Care 30(2): 120-4; Quiz 125-7, 2014

Human Botulism Immune Globulin for the Treatment of Infant Botulism. Yearbook of Pediatrics 2007: 242-243, 2007

Development of infant botulism in a 3-year-old female with neuroblastoma following autologous bone marrow transplantation: potential use of human botulism immune globulin. Bone Marrow Transplantation 13(3): 345-347, 1994

An unusual case of botulism and the successful use of human botulism immune globulin in a 3 year old female with neuroblastoma following autologous bone marrow transplantation. Blood 82(10 Suppl. 1): 641A, 1993

Outbreak of type A botulism and development of a botulism surveillance and antitoxin release system in Argentina. JAMA 281(14): 1334-8 1340, 1999